Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Graphite Bio (GRPH)
NASDAQ:GRPH
Holding GRPH?
Track your performance easily
GRPH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.51 - $20.16
Previous Close$16.2
Volume328.40K
Average Volume (3M)40.55K
Market Cap
$134.78M
Enterprise Value-$49.12M
Total Cash (Recent Filing)$184.26M
Total Debt (Recent Filing)$362.00K
Price to Earnings (P/E)―
Beta0.63
Next Earnings
May 09, 2024EPS EstimateN/A
Last Dividend Ex-Date
Mar 22, 2024Dividend YieldN/A
Share Statistics
EPS (TTM)-15.34
Shares Outstanding58,236,926
10 Day Avg. Volume1,074,934
30 Day Avg. Volume40,548
Standard Deviation0.20
R-Squared0.00258
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)1.01
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.50
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Graphite Bio News
PremiumCompany Announcements
Graphite Bio’s Strategic Merger and Rebranding to LENZ Therapeutics
PremiumCompany Announcements
Graphite Bio Approves Merger, Name Change, and Stock SplitPremiumPre-Earnings
Is GRPH a Buy, Before Earnings?
PremiumCompany Announcements
Graphite Bio Announces Special Dividend Amid Lenz MergerRisk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
GRPH FAQ
What was Graphite Bio’s price range in the past 12 months?
Graphite Bio lowest stock price was $9.51 and its highest was $20.16 in the past 12 months.
What is Graphite Bio’s market cap?
Currently, no data Available
When is Graphite Bio’s upcoming earnings report date?
Graphite Bio’s upcoming earnings report date is May 09, 2024 which is 140 days ago.
How were Graphite Bio’s earnings last quarter?
Graphite Bio released its earnings results on Mar 18, 2024. The company reported -$2.766 earnings per share for the quarter, missing the consensus estimate of -$0.905 by -$1.861.
Is Graphite Bio overvalued?
According to Wall Street analysts Graphite Bio’s price is currently Overvalued.
Does Graphite Bio pay dividends?
Graphite Bio pays a Notavailable dividend of $1.03 which represents an annual dividend yield of N/A. See more information on Graphite Bio dividends here
What is Graphite Bio’s EPS estimate?
Graphite Bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Graphite Bio have?
Graphite Bio has 8,319,561 shares outstanding.
What happened to Graphite Bio’s price movement after its last earnings report?
Graphite Bio reported an EPS of -$2.766 in its last earnings report, missing expectations of -$0.905. Following the earnings report the stock price went down -3.289%.
Which hedge fund is a major shareholder of Graphite Bio?
Among the largest hedge funds holding Graphite Bio’s share is Western Standard Llc. It holds Graphite Bio’s shares valued at N/A.
---
Graphite Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 175.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.6%
Last 30 Days ▲ 12.0%
Last 30 Days ▲ 12.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.28%
12-Months-Change
Fundamentals
Return on Equity
-51.95%
Trailing 12-Months
Asset Growth
-41.46%
Trailing 12-Months
Company Description
Graphite Bio
Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations.
---
GRPH Stock 12 Month Forecast
Average Price Target
―Technical Analysis
BioMarin Pharmaceutical
―
Crispr Therapeutics AG
―
Editas Medicine
―
Intellia Therapeutics
―
---